[go: up one dir, main page]

MX2016001635A - Probiotico para el llanto infantil excesivo. - Google Patents

Probiotico para el llanto infantil excesivo.

Info

Publication number
MX2016001635A
MX2016001635A MX2016001635A MX2016001635A MX2016001635A MX 2016001635 A MX2016001635 A MX 2016001635A MX 2016001635 A MX2016001635 A MX 2016001635A MX 2016001635 A MX2016001635 A MX 2016001635A MX 2016001635 A MX2016001635 A MX 2016001635A
Authority
MX
Mexico
Prior art keywords
probiotico
plain
bacterial composition
composition
dietary supplement
Prior art date
Application number
MX2016001635A
Other languages
English (en)
Other versions
MX380752B (es
Inventor
CUÑE CASTELLANA Jordi
Espadaler Mazo Jordi
Lázaro Mallén Elísabet
Original Assignee
Ab-Biotics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab-Biotics S A filed Critical Ab-Biotics S A
Publication of MX2016001635A publication Critical patent/MX2016001635A/es
Publication of MX380752B publication Critical patent/MX380752B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/206—Bacterial extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/41—Pediococcus
    • A23V2400/427—Pentosaceus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pediatric Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención proporciona una composición bacteriana que comprende de 104 a 1012 ufc/g de células de Pediococcus pentosaceus que tienen la capacidad de inducir la producción de interleucina-10 para reducir la inflamación en el tracto intestinal entre otras características. Por lo tanto, la composición bacteriana es útil en la mejora de llanto excesivo en los bebés. En particular, las células de Pediococcus pentosaceus son de la cepa depositada como CECT 8330. La composición bacteriana puede estar en la forma de un suplemento dietético, un medicamento, una fórmula para bebés y un producto alimenticio. En particular, la composición está en la forma de un suplemento dietético para lactantes, en forma de suspensión oleosa.
MX2016001635A 2013-08-09 2014-08-07 Probiótico para el llanto infantil excesivo. MX380752B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382324 2013-08-09
PCT/EP2014/066970 WO2015018883A2 (en) 2013-08-09 2014-08-07 Probiotic for infantile excessive crying

Publications (2)

Publication Number Publication Date
MX2016001635A true MX2016001635A (es) 2016-10-07
MX380752B MX380752B (es) 2025-03-12

Family

ID=49029044

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001635A MX380752B (es) 2013-08-09 2014-08-07 Probiótico para el llanto infantil excesivo.
MX2021000259A MX2021000259A (es) 2013-08-09 2016-02-05 Probiotico para el llanto infantil excesivo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000259A MX2021000259A (es) 2013-08-09 2016-02-05 Probiotico para el llanto infantil excesivo.

Country Status (17)

Country Link
US (2) US10265351B2 (es)
EP (1) EP3030247B1 (es)
JP (1) JP6643988B2 (es)
KR (1) KR102084825B1 (es)
CN (2) CN111676171B (es)
AU (1) AU2014304535B2 (es)
BR (1) BR112016002650A2 (es)
CA (2) CA3176938A1 (es)
DK (1) DK3030247T3 (es)
EA (1) EA034531B9 (es)
ES (1) ES2683190T3 (es)
HU (1) HUE039336T2 (es)
MX (2) MX380752B (es)
PH (1) PH12016500271A1 (es)
PL (1) PL3030247T3 (es)
TW (1) TW201536302A (es)
WO (1) WO2015018883A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2018202657A1 (en) * 2017-05-05 2018-11-08 Nestec S.A. Treatment of infant colic
JP6836756B2 (ja) * 2017-09-21 2021-03-03 光博 岡野 口腔細菌叢中の構成叢比を予測する方法
JP7197204B2 (ja) * 2017-11-10 2022-12-27 エムティックスバイオ カンパニー リミテッド 新規のｐｅｄｉｏｃｏｃｃｕｓ ｐｅｎｔｏｓａｃｅｕｓ ａｂ１６００１１菌株及びこれを含む組成物
KR102434641B1 (ko) * 2018-11-23 2022-08-23 한국식품연구원 페디오코쿠스 펜토사세우스를 이용한 호흡기 기능 개선용 식품 조성물
WO2021231504A1 (en) * 2020-05-12 2021-11-18 Rpi Consulting Llc Systems and methods for isolating and testing blood for biomarkers and genetic material
CN117858714A (zh) * 2021-07-13 2024-04-09 Ab－生物学有限公司 用于治疗肠道通透性增加的益生菌组合物
IL315475A (en) 2022-03-08 2024-11-01 Equashield Medical Ltd A position for transferring liquids in a robotic system for preparing medicines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
RU2468807C2 (ru) * 2007-02-28 2012-12-10 Мед Джонсон Нутришен Компани Детское питание, содержащее инактивированный пробиотик
IT1400821B1 (it) * 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico
WO2010103132A1 (es) * 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
JP5531321B2 (ja) * 2009-03-31 2014-06-25 キッコーマン株式会社 Ｉｌ−１０産生促進作用を有する免疫賦活組成物
TWI415942B (zh) * 2009-10-15 2013-11-21 Food Industry Res & Dev Inst 生產胞外多醣的方法以及一新穎的乳酸小球菌分離株
PH12012501050A1 (en) * 2009-12-08 2013-02-04 Nestec Sa Infant formula with probiotics and milk fat globule membrane components
SG191393A1 (en) * 2010-12-31 2013-08-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes

Also Published As

Publication number Publication date
AU2014304535B2 (en) 2017-06-15
JP6643988B2 (ja) 2020-02-12
ES2683190T3 (es) 2018-09-25
EP3030247A2 (en) 2016-06-15
MX380752B (es) 2025-03-12
CN105555283B (zh) 2020-08-11
EA034531B9 (ru) 2020-03-19
CA3176938A1 (en) 2015-02-12
MX2021000259A (es) 2021-03-25
US20180008652A1 (en) 2018-01-11
DK3030247T3 (en) 2018-08-13
CA2920461A1 (en) 2015-02-12
HUE039336T2 (hu) 2018-12-28
EA201690196A1 (ru) 2016-12-30
TW201536302A (zh) 2015-10-01
WO2015018883A3 (en) 2015-04-02
CN105555283A (zh) 2016-05-04
WO2015018883A2 (en) 2015-02-12
KR102084825B1 (ko) 2020-03-04
BR112016002650A2 (pt) 2017-09-12
CA2920461C (en) 2023-01-03
EA034531B1 (ru) 2020-02-18
PL3030247T3 (pl) 2019-02-28
US20160184371A1 (en) 2016-06-30
KR20160046826A (ko) 2016-04-29
PH12016500271A1 (en) 2016-05-16
EP3030247B1 (en) 2018-05-16
CN111676171A (zh) 2020-09-18
AU2014304535A1 (en) 2016-03-10
US10265351B2 (en) 2019-04-23
CN111676171B (zh) 2023-06-06
JP2016526918A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
MX2016001635A (es) Probiotico para el llanto infantil excesivo.
CO2018002394A2 (es) Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa
MX2021000715A (es) Composiciones y metodos para tratar trastornos metabolicos.
MX2013007676A (es) Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
MX2019003787A (es) Bacterias del ácido láctico tolerantes a antisépticos.
PH12017500467A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of malabsorption or maldigestion in infants or children
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
FI3389407T3 (fi) Ravintokoostumus ja äidinmaidonkorvike de novo myelinaation edistämiseksi
RU2015122495A (ru) Содержащие треонат магния питательные композиции и их применение
EA201592003A1 (ru) Микропищевые добавки для иммунитета
PH12012501704B1 (en) Nutritional compositions
TN2016000005A1 (en) Substituted pyrazolo-pyridinamines
MX2016006503A (es) Formulacion de bifidobacterium lactis ncc 2818 tratada con calor que reduce las manifestaciones alergicas.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
AR099863A1 (es) Método para reducir el riesgo de hipersensibilidad al dolor visceral
AR105095A1 (es) Concentrado de jugo de fruta para una marinada
PH12017500466A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children
BR112015012220A2 (pt) composição simbiótica e uso da mesma
CL2014000917A1 (es) Polvo base a partir de frambuesa roja rubus idaeus y zeolita activada y micronizada para atenuar la adiccion a la nicotina, proceso para su preparación y su uso.
BR112014015193A8 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico
MX350277B (es) Celulas b. texasporus deficientes de esporulacion y metodos para inactivacion eficiente y rentable y su uso.
EA201400587A1 (ru) Пептид, обладающий ноотропным действием, композиции на его основе и способы их применения
PL401911A1 (pl) Zastosowanie preparatu o wlasciwosciach immunoregulatorowych
CN302212774S (zh) 儿童餐椅(bch202a)